Cargando…
Patients with relapsed/refractory chronic lymphocytic leukaemia may benefit from inclusion in clinical trials irrespective of the therapy received: a case-control retrospective analsysis
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635190/ https://www.ncbi.nlm.nih.gov/pubmed/26430727 http://dx.doi.org/10.1038/bcj.2015.78 |
| _version_ | 1782399474084085760 |
|---|---|
| author | Esteban, D Tovar, N Jiménez, R Santacruz, R Baumann, T Pastor, MaC de la Riva, A Carrera, E Chaves, S Royo, C Navarro, A Rodríguez, S Ayuso, C Riu, G Creus, N Gómez, B Giné, E López-Guillermo, A Delgado, J |
| author_facet | Esteban, D Tovar, N Jiménez, R Santacruz, R Baumann, T Pastor, MaC de la Riva, A Carrera, E Chaves, S Royo, C Navarro, A Rodríguez, S Ayuso, C Riu, G Creus, N Gómez, B Giné, E López-Guillermo, A Delgado, J |
| author_sort | Esteban, D |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4635190 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46351902015-11-25 Patients with relapsed/refractory chronic lymphocytic leukaemia may benefit from inclusion in clinical trials irrespective of the therapy received: a case-control retrospective analsysis Esteban, D Tovar, N Jiménez, R Santacruz, R Baumann, T Pastor, MaC de la Riva, A Carrera, E Chaves, S Royo, C Navarro, A Rodríguez, S Ayuso, C Riu, G Creus, N Gómez, B Giné, E López-Guillermo, A Delgado, J Blood Cancer J Letter to the Editor Nature Publishing Group 2015-10 2015-10-02 /pmc/articles/PMC4635190/ /pubmed/26430727 http://dx.doi.org/10.1038/bcj.2015.78 Text en Copyright © 2015 Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| spellingShingle | Letter to the Editor Esteban, D Tovar, N Jiménez, R Santacruz, R Baumann, T Pastor, MaC de la Riva, A Carrera, E Chaves, S Royo, C Navarro, A Rodríguez, S Ayuso, C Riu, G Creus, N Gómez, B Giné, E López-Guillermo, A Delgado, J Patients with relapsed/refractory chronic lymphocytic leukaemia may benefit from inclusion in clinical trials irrespective of the therapy received: a case-control retrospective analsysis |
| title | Patients with relapsed/refractory chronic lymphocytic leukaemia may benefit from inclusion in clinical trials irrespective of the therapy received: a case-control retrospective analsysis |
| title_full | Patients with relapsed/refractory chronic lymphocytic leukaemia may benefit from inclusion in clinical trials irrespective of the therapy received: a case-control retrospective analsysis |
| title_fullStr | Patients with relapsed/refractory chronic lymphocytic leukaemia may benefit from inclusion in clinical trials irrespective of the therapy received: a case-control retrospective analsysis |
| title_full_unstemmed | Patients with relapsed/refractory chronic lymphocytic leukaemia may benefit from inclusion in clinical trials irrespective of the therapy received: a case-control retrospective analsysis |
| title_short | Patients with relapsed/refractory chronic lymphocytic leukaemia may benefit from inclusion in clinical trials irrespective of the therapy received: a case-control retrospective analsysis |
| title_sort | patients with relapsed/refractory chronic lymphocytic leukaemia may benefit from inclusion in clinical trials irrespective of the therapy received: a case-control retrospective analsysis |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635190/ https://www.ncbi.nlm.nih.gov/pubmed/26430727 http://dx.doi.org/10.1038/bcj.2015.78 |
| work_keys_str_mv | AT esteband patientswithrelapsedrefractorychroniclymphocyticleukaemiamaybenefitfrominclusioninclinicaltrialsirrespectiveofthetherapyreceivedacasecontrolretrospectiveanalsysis AT tovarn patientswithrelapsedrefractorychroniclymphocyticleukaemiamaybenefitfrominclusioninclinicaltrialsirrespectiveofthetherapyreceivedacasecontrolretrospectiveanalsysis AT jimenezr patientswithrelapsedrefractorychroniclymphocyticleukaemiamaybenefitfrominclusioninclinicaltrialsirrespectiveofthetherapyreceivedacasecontrolretrospectiveanalsysis AT santacruzr patientswithrelapsedrefractorychroniclymphocyticleukaemiamaybenefitfrominclusioninclinicaltrialsirrespectiveofthetherapyreceivedacasecontrolretrospectiveanalsysis AT baumannt patientswithrelapsedrefractorychroniclymphocyticleukaemiamaybenefitfrominclusioninclinicaltrialsirrespectiveofthetherapyreceivedacasecontrolretrospectiveanalsysis AT pastormac patientswithrelapsedrefractorychroniclymphocyticleukaemiamaybenefitfrominclusioninclinicaltrialsirrespectiveofthetherapyreceivedacasecontrolretrospectiveanalsysis AT delarivaa patientswithrelapsedrefractorychroniclymphocyticleukaemiamaybenefitfrominclusioninclinicaltrialsirrespectiveofthetherapyreceivedacasecontrolretrospectiveanalsysis AT carrerae patientswithrelapsedrefractorychroniclymphocyticleukaemiamaybenefitfrominclusioninclinicaltrialsirrespectiveofthetherapyreceivedacasecontrolretrospectiveanalsysis AT chavess patientswithrelapsedrefractorychroniclymphocyticleukaemiamaybenefitfrominclusioninclinicaltrialsirrespectiveofthetherapyreceivedacasecontrolretrospectiveanalsysis AT royoc patientswithrelapsedrefractorychroniclymphocyticleukaemiamaybenefitfrominclusioninclinicaltrialsirrespectiveofthetherapyreceivedacasecontrolretrospectiveanalsysis AT navarroa patientswithrelapsedrefractorychroniclymphocyticleukaemiamaybenefitfrominclusioninclinicaltrialsirrespectiveofthetherapyreceivedacasecontrolretrospectiveanalsysis AT rodriguezs patientswithrelapsedrefractorychroniclymphocyticleukaemiamaybenefitfrominclusioninclinicaltrialsirrespectiveofthetherapyreceivedacasecontrolretrospectiveanalsysis AT ayusoc patientswithrelapsedrefractorychroniclymphocyticleukaemiamaybenefitfrominclusioninclinicaltrialsirrespectiveofthetherapyreceivedacasecontrolretrospectiveanalsysis AT riug patientswithrelapsedrefractorychroniclymphocyticleukaemiamaybenefitfrominclusioninclinicaltrialsirrespectiveofthetherapyreceivedacasecontrolretrospectiveanalsysis AT creusn patientswithrelapsedrefractorychroniclymphocyticleukaemiamaybenefitfrominclusioninclinicaltrialsirrespectiveofthetherapyreceivedacasecontrolretrospectiveanalsysis AT gomezb patientswithrelapsedrefractorychroniclymphocyticleukaemiamaybenefitfrominclusioninclinicaltrialsirrespectiveofthetherapyreceivedacasecontrolretrospectiveanalsysis AT ginee patientswithrelapsedrefractorychroniclymphocyticleukaemiamaybenefitfrominclusioninclinicaltrialsirrespectiveofthetherapyreceivedacasecontrolretrospectiveanalsysis AT lopezguillermoa patientswithrelapsedrefractorychroniclymphocyticleukaemiamaybenefitfrominclusioninclinicaltrialsirrespectiveofthetherapyreceivedacasecontrolretrospectiveanalsysis AT delgadoj patientswithrelapsedrefractorychroniclymphocyticleukaemiamaybenefitfrominclusioninclinicaltrialsirrespectiveofthetherapyreceivedacasecontrolretrospectiveanalsysis |